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ABSTRACT
Carbapenems are β-lactam antibiotics reserved for the treatment of severe
microbial infections, especially those targeting the Enterobacteriaceae. Introduced in
the 1980s, carbapenems have been used successfully in hospitals, and in the 1990s
resistance was discovered. Carbapenem resistance is conferred through the production
of carbapenemases. In the U.S., the most common carbapenemase is Klebsiella
pneumoniae carbapenemase (KPC). In 2012, the National Healthcare Safety Network
reported a carbapenem resistance rate of 13.0% among Klebsiella pneumoniae
infections, and indicated that the mortality rate associated with carbapenem resistant
Enterobacteriaceae (CRE) infections ranged from 48.0-71.9%. According to the Food
and Drug Administration (FDA), carbapenem resistance is observed when a pure culture
has a minimum inhibitory concentration (MIC) ≥ 4 g/ml as determined through
antibiotic susceptibility testing (AST).In 2012, a lower MIC for carbapenem antibiotics
was established for KPCs by the Clinical and Laboratory Standards Institute (CLSI) (i.e.,
MICs 1 - 4 g/ml are designated resistant), but these criteria have not been endorsed by
the FDA. Data are needed to determine the percentage of clinical isolates with
carbapenem MIC between 1 and 4 g/ml that are truly resistant. Determining the
presence of the KPC gene is important because the use of carbapenems in patients with
MIC between 1- 4 g/ml may have poor clinical outcomes. Conversely, if lacking the KPC
gene, carbapenems may still be indicated. The objectives of this study were to
determine the presence of the KPC gene, the carbapenem AST profiles of clinical
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isolates, and the resistance rates based on the previous and current CLSI criteria. This
study involved 56 suspected CRE clinical isolates from Las Vegas, Nevada, which were
analyzed by culture, AST, and polymerase chain reaction to detect the KPC gene. The
prevalence of the blaKPC gene in our CRE isolates was 83.3%, and the prevalence was
94.7% among our Klebsiella pneumoniae isolates. Our data showed no statistically
significant difference between the previous and the current CLSI criteria in defining
carbapenem resistance among the Enterobacteriaceae. The results from this study
helped determine the prevalence of the KPC gene and antimicrobial susceptibility
profiles among CRE isolates in Las Vegas. These may be useful in improving antibiotic
stewardship in Nevada.
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INTRODUCTION
The Enterobacteriaceae is a family of bacteria with many different genera and
species. Members of this family are gram negative, non-spore forming, and facultative
anaerobes, which include many opportunistic and pathogenic species. Most of these
organisms are present in the intestinal tracts of humans and animals, while some are
freely living in soil, water and sewage. Opportunistic Enterobacteriaceae cause disease
when the immunity is low, and are usually in the intestinal and skin flora of humans and
animals, but can produce serious infection outside their natural habitat. Clinical isolates
of Enterobacteriaceae that are commonly seen in acute and long term care centers are
Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis (Mahon, Manuselis, &
Lehman, 2010). Other common genera include Shigella spp., Salmonella spp.,
Citrobacter spp., Yersinia, Serratia spp., etc. (Mahon et al., 2010). These organisms are
notorious for causing mild to severe infections, such as cystitis, pneumonia, meningitis,
bacteremia, septicemia, and wound infections, when immunity is compromised
(Schwaber & Carmeli, 2008).
Klebsiella pneumoniae is a common opportunistic and nosocomial organism. It is
an encapsulated non-motile gram negative bacterium found as normal flora of the
human skin, mouth and the intestines. However, it is capable of causing serious
infection. The distinct polysaccharide capsule of Klebsiella pneumoniae offers protection
against phagocytosis and antimicrobial absorption, and contributes to its virulence
(Mahon, Manuselis, & Lehman, 2000). The frequent colonization by Klebsiella
pneumoniae of the respiratory tracts of hospitalized patients makes it a common cause
1

of lower respiratory infection, especially among immunocompromised patients,
newborns and patients on respirators. K. pneumoniae remains the fourth and fifth most
common cause of acute pneumonia and bacteremia in hospital intensive care units,
respectively (Centers for Disease Control and Prevention, 2003). It can also cause
serious infections outside the hospital, and has been estimated to be responsible for 6%
- 8% of community acquired pneumonia (Jong, Hsiue, Chen, Chang, & Chen, 1995).
Other community acquired infections caused by K. pneumoniae include wound
infections, abscesses, and urinary tract infections.
Cephalosporins and the β-lactams are common antimicrobial agents used
successfully in the treatment of infections caused by Klebsiella pneumoniae and other
Enterobacteriaceae. In the past, 3rd and 4th generation cephalosporins were first choice in

the treatment of Enterobacteriaceae infections. However, resistance of
Enterobacteriaceae to these antibiotics has been well documented in recent times
(Paterson et al., 2003; Saurina, Quale, Manikal, Oydna, & Landman, 2000).
Carbapenems are β-lactamase inhibitor antibiotics. The parent or model compound of
carbapenems is thienamycin, a compound from Streptomyces cattleya which was first
reported in 1976 (Ratcliffe & Albers-Schonberg, 1982). Thienamycin has a hydroxyethyl
side chain, a departure from the conventional structures of penicillin and
cephalosporins (Papp-Wallace, Endimiani, Taracila, & Bonomo, 2011). This
stereochemistry and structure are key to their extensive activity and potency.
Unfortunately, thienamycin is unstable in aqueous solution, highly reactive and very

sensitive to mild base hydrolysis. This instability stimulated the search for more stable
thienamycin analogs.
Carbapenems, such as Ertapenem, Imipenem, Meropenem, and Doripenem are
analogs of thienamycin, and unlike thienamycin, they are more stable and less sensitive
to base hydrolysis (Branch et al., 1998). They possess the widest spectrum of
antibacterial activities and potency of all the β-lactam antibiotics and are effective
against gram negative and gram positive organisms (Bassetti, Nicolini, Esposito, Righi, &
Viscoli, 2009; Papp-Wallace et al., 2011). Carbapenems are active against the
chromosomal cephalosporinases and extended-spectrum β-lactamases, both of which
are found in resistant gram-negative organisms (G. A. Jacoby & Munoz-Price, 2005;
Queenan & Bush, 2007). Another mechanism of action of carbapenems involves the
destruction of bacterial membranes through porin proteins leading to permeability.
Carbapenems form part of a new generation of antibiotics that are reserved for the
treatment of severe and resistant microbial infections, especially those caused by
Enterobacteriaceae. Since their discovery in 1985, carbapenems have been remarkably
effective in the treatment of severe infections, and in some situations, they are
regarded as the last resort for treatment of infections caused by extended spectrum βlactamase (ESBL) organisms (Remington, 1985).
Carbapenem resistance first appeared sporadically in the mid-1990s, in places
such as Spain (Corbella et al., 2000). Though the resistance was uncommon, in recent
years, carbapenem resistant Enterobacteriaceae (CRE) outbreaks have been
progressively increasing (Queenan & Bush, 2007; Schwaber et al., 2008). Beyond

Enterobacteriaceae, many non-fermenting gram negatives (e.g., Pseudomonas and
Acinetobacter species) and some gram positives (e.g., Staphylococcus, Streptococcus,
Enterococcus, and Nocardia species) are also becoming resistant to carbapenems. This
pattern represents a major public health threat in our society. In the U.S., CREs were
first discovered in North Carolina in 2001 (Yigit et al., 2001). Since then, outbreaks have
been reported throughout the country, especially in the northeast region (Landman et
al., 2007; Queenan & Bush, 2007).
Unlike Methicillin Resistant Staphylococcus aureus (MRSA) resistance, which is
mediated by a single mechanism in a single bacterial species, the mechanisms of
carbapenem resistance are complex because they involve a broad range of organisms
and are mediated by different mechanisms, such as the production of β-lactamases,
efflux pump and porin mutations. Carbapenemases are β-lactamases with versatile
hydrolytic capacities and are capable of hydrolyzing the beta-lactam ring of
carbapenems. They are also capable of hydrolyzing penicillins, monobactams, and
cephalosporins. Carbapenemases are the most prominent β-lactamases to neutralize
carbapenems (Nordmann & Poirel, 2002; Queenan & Bush, 2007).
Carbapenemases are enzymes that catalyze the breakdown of carbapenems.
They confer resistance to carbapenems and belong to the molecular classes A, B, and D
of the β-lactamases. Class A and D enzymes have a serine-based hydrolytic mechanism,
while class B uses zinc in their active site. Klebsiella pneumoniae carbapenemase (KPC)
is a class B β-lactamase and is the most common form of carbapenemase implicated in
CRE outbreaks in the U.S. Sometimes sporadic outbreaks involve the New Delhi

Metallo-β-lactamase (NDM-1), a variant of the Metallo- β -lactamases (MBL). Other
forms of carbapenem resistance, such as the production of AmpC-type enzyme with a
combination of cephalosporinase and porin loss are increasingly becoming common
(Bradford et al., 2004; Crowley, Benedi, & Domenech-Sanchez, 2002; Queenan & Bush,
2007). Other countries with KPC outbreaks include Greece, Israel, Colombia, and Puerto
Rico (Leavitt, Navon-Venezia, Chmelnitsky, Schwaber, & Carmeli, 2007).
The genes coding for the KPC are located on plasmids or the mobile units of
Klebsiella DNA. This property makes the KPC gene easily transmissible. Not surprisingly,
KPC genes have been successfully isolated from other Enterobacteriaceae, such as
Escherichia coli, Serratia marcescens, Pseudomonas, and Acinetobacter baumannii
(Deshpande, Jones, Fritsche, & Sader, 2006; Patel & Bonomo, 2011; Villegas et al.,
2007).
Klebsiella pneumoniae Sequence Type 258 (ST258), which is a single locus variant
of Sequence Type 11 (ST11), is the most common clone or strain type of Klebsiella
implicated in the KPC-producing K. pneumoniae. This strain accounts for over 70% of the
CDC’s Klebsiella pneumoniae Pulse Field Gel Electrophoresis (PFGE) database (Kitchel et
al., 2009). ST258 isolates demonstrate great diversity in molecular characteristics and
epidemiology, and have been identified in KPC-producing isolates from Israel, Finland,
Poland, Italy, Germany, Greece, Norway and Sweden, supporting possible international
dissemination (Cuzon, Naas, Demachy, & Nordmann, 2008; Qi et al., 2011; Samuelsen et
al., 2009). K. pneumoniae Sequence Type 14 (ST14) has also been identified, but it is
associated with KPC-producing isolates from the Midwest and Western U.S., (Kitchel et

al., 2009). ST11, which is closely related to ST258, is the dominant KPC-producing K.
pneumoniae in China, and it accounts for greater than 80% of China’s KPC-producing K.
pneumoniae isolates (Qi et al., 2011)
Epidemiology of CRE
CREs appeared to be uncommon before 1992; however, over the last decades
CRE infections have become commonly reported (Braykov, Eber, Klein, Morgan, &
Laxminarayan, 2013). CRE outbreaks have been reported in at least 43 states in the U.S.
and many other countries such as Brazil, Israel, Greece, and India (Andrade et al., 2011;
Centers for Disease Control and Prevention, 2012a; Gupta, Limbago, Patel, & Kallen,
2011; Pournaras et al., 2009). The Centers for Disease Control and Prevention (CDC)
monitor the true incidence of infections caused by CREs; unfortunately, CRE infections
are not notifiable in every state. The CDC uses information from two surveillance
systems; namely, the Emerging Infection Program (EIP) and the National Healthcare
Safety Network (NHSN), to monitor CRE infection incidences. The NHSN reviews data
from all facilities performing surveillance for Central-Line-Associated Bloodstream
Infections (CLABSI) together with data from Catheter Associated Urinary Tract
Infections (CAUTIs). These infections, mainly caused by Enterobacteriaceae, such as E.
coli, K. pneumoniae, K. oxytoca, Enterobacter cloacae, and Enterobacter aerogenes
have showed non-susceptibility to Ertapenem, Imipenem, Doripenem or Meropenem.
The EIP uses population-based CRE surveillance data from three selected sites in the
U.S.

Data from the National Nosocomial Infection Surveillance (NNIS), (before it was
replaced by NHSN) reported that between 1986 and 1990, the rate of nonsusceptibility to carbapenem in 1,825 isolates of Enterobacter investigated was 2.3%
(Gaynes & Culver, 1992). It also reported that the percentage of Enterobacteriaceae
that were carbapenem resistant rose from 1.2% in 2001 to 4.2% in 2011 (Jacob et al.,
2013). These rates vary among Enterobacteriaceae and have increased the most in
Klebsiella species, from 1.6 % to 10.8 %. Data from The Surveillance Network (TSN),
which represents an electronic repository of susceptibility test results from over 300
laboratories across the United States, demonstrated an increase from 0% to 1.2%
among all CREs, and 0% to 5.3% among Klebsiella species (Jacob et al., 2013). Data
from the Meropenem Yearly Susceptibility Test Information Collection Program
(MYSTICP), between 2006 and 2007, reported that resistance among Klebsiella
pneumoniae exceeded 8% before falling momentarily to 5.6% in 2008 (Braykov et al.,
2013; Rhomberg & Jones, 2009). The NHSN, in 2004, reported a CRE rate of 10.8%
among Klebsiella pneumoniae; that stabilized at 13% in 2012 (Hidron et al., 2008;
Sievert et al., 2013). The Washoe County Health District in Nevada in 2011, reported
an incidence rate of 5%, after 15 months of CRE surveillance on 111 clinical isolates
tested with the Modified Hodge Test at the Nevada State Public Health Laboratory
(Chen, 2011). Interestingly, the majority of the CRE isolates in Washoe County were
Enterobacter cloacae, an organism that has shown resistance to carbapenems.
During the first half of 2012, a surveillance of CAUTIs and CLABSI in acute-care
hospitals in the U.S. reported that 181 of 3,918 (4.6%) centers surveyed reported

detecting one or more infections with CREs. Long-term acute care hospitals (LTACHs)
have reported a rate of 17.8% in at least one outbreak of CRE infections, while, in shortterm acute care hospitals, rates were 3.9%. The highest percentage of hospitals with
CREs were in the northeast U.S., where rates were up to 30%. In the 2012 NHSN report,
the state of Nevada was included as one of 43 states with CRE infections in the U.S.
(Jacob et al., 2013).
Detection of CRE
The most often used method for CRE detection is the measurement of Minimal
Inhibitory Concentration (MIC) through automated susceptibility testing machines. MIC
is a quantitative measurement of antibiotic activities, and it is defined as the minimum
concentration of an antibiotic that can inhibit visible microbial growth under normal
conditions (Mayer, 2010; Sievert et al., 2013). Carbapenem resistance is defined for all
organisms as an MIC result of Intermediate (I) or Resistant (R) to carbapenems on any
antibiotic susceptibility test (Sievert et al., 2013). According to the FDA, an organism is
classified as resistant to carbapenem if the pure culture shows a microbial breakpoint
with an MIC ≥ 4 g/ml during susceptibility testing (Bulik et al., 2010). Microbial
breakpoint refers to the MIC at which an organism is described as susceptible or
resistant to a given antibiotic. It is important that the MIC of antibiotics be lower than
their breakpoint.
Carbapenem resistance can also be determined using the disk diffusion method.
A type of disk diffusion method used is the Modified Hodge Test (MHT), a form of
susceptibility testing that phenotypically determines the presence of the

carbapenemase enzyme (Clinical and Laboratory Standards Institute, 2012). The MHT
has been regarded as the confirmatory test for CRE; however, limitations to this method
include an inability to differentiate the class of carbapenemase involved, unusable for
non-fermenting organisms, long duration of testing (up to 36 hours for the results to be
available), a low positive predictive valve, and variable sensitivity that ranges from 76%
to 100% (Amjad et al., 2011; Haji Hashemi et al.; Mathers, Carroll, Sifri, & Hazen, 2013;
Tsakris et al., 2010).
The use of boronic acid is another phenotypic test for detecting CREs and has
demonstrated an excellent ability in detecting KPCs, especially among Klebsiella
pneumoniae isolates (Doi et al., 2008). Boronic acid alone or in combination with disks
containing Imipenem, Meropenem or cefepime, showed 100% sensitivity and specificity
in identifying KPC producers (Tsakris et al., 2009). Unfortunately, this method is not
commercially available, and like the MHT, it requires an additional day before results are
available.
Real-time Polymerase Chain Reaction (PCR) is a quick, accurate and effective
method of CRE detection; it can detect CRE resistance genes, such as the blaKPC, the
NDM-1, MBL, and the AmpC genes (Endimiani et al., 2010). PCR and other molecular
tests have the highest specificity in identification and confirmation of the underlying
carbapenemases (Nordmann et al., 2012). The sensitivity of real-time PCR in detecting
the blaKPC gene ranges from 92.9% to 96.4% while the specificity is as high as 99.6%
(Francis, Wu, Della-Latta, Shi, & Whittier, 2012). However, the high cost and the
technical expertise required, in addition to the fact that only the target gene (e.g.,

carbapenemase gene) amplifies, are significant limitations to the use of PCR and other
molecular tests in CRE detection (Yang & Rothman, 2004).
A significant problem in CRE laboratory detection is the fact that some bacterial
isolates carry the KPC gene, while having susceptible, but elevated MICs (Clinical and
Laboratory Standards Institute, 2009). This means that some isolates producing
carbapenemase may test susceptible to carbapenems. In these situations, CREs will not
be identified, thus posing an infection control problem. This has caused some
automated AST methods to fail in detecting low levels of carbapenemase resistance.
To tackle this problem, the Clinical and Laboratory Standards Institute (CLSI), in
2009, published a recommendation that carbapenem susceptible Enterobacteriaceae
with susceptible, but elevated MIC or with a reduced disk diffusion zone, be tested for
the presence of the carbapenemase enzyme using the Modified Hodge Test.
Furthermore, in 2010, the CLSI officially changed the carbapenem resistance criteria to
ensure that KPC-producing organisms were not missed. This, also, removed the need
for secondary testing with MHT among isolates with susceptible but elevated MICs.
Therefore, a lower level of MIC for antibiotic resistance was established for CREs; these
criteria were further revised in 2012 (Clinical and Laboratory Standards Institute, 2012).
The previous and the current CLSI criteria are shown in Table 1.

Table 1: Performance Standards for Antimicrobial Susceptibility Testing.
Previous Breakpoints (M100-S19)a
MIC (g/ml)
Agent

Current Breakpoints (M100-S22)b
MIC (g/ml)

S

I

R

S

I

R

Doripenem

-

-

-

≤1

2

≤4

Ertapenem

≤2

4

≥8

≤0.5

1

≥2

Imipenem

≤4

8

≥16

≤1

2

≥4

Meropenem
≤4
8
≥16
≤1
2
≥4
S = Susceptible; I= Intermediate; R = Resistant; MIC = minimum inhibitory concentration
a

2009 CLSI criteria

b

2012 CLSI criteria

Source: Twenty Second Informational Supplement (January 2012). CLSI document M100-S22.
Wayne, Pennsylvania, 2012.

Diagnostic kit manufacturers and clinical laboratories must have their kits FDAcleared before they can be used with patient isolates; these recent changes have led to
confusion (Gupta et al., 2011). As of late 2010, about 80% of clinical laboratories still use
FDA-cleared AST systems with FDA breakpoints (Paxton, 2010). An Indiana Sentinel
Laboratories CRE Testing Capacity Survey that studied the adoption rate of the new CLSI
criteria noted that only about 37% of laboratories in Indiana used the CLSI M100-S21
criteria (Jean, 2011). In Rhode Island, a statewide assessment of the impact of the new
CLSI criteria conducted in 2012 found that 100% of the 11 clinical laboratories
representing all the state’s acute care centers did not use the new CLSI criteria
(Alexander, 2013). At the same time, only 27% of these laboratories in Rhode Island
were interested in conducting the necessary verification studies to implement the
current CLSI criteria. The majority of laboratories and hospitals preferred to wait until

the manufacturers update their AST systems when the FDA accepts the new CLSI criteria
(Alexander, 2013). These are undoubtedly key obstacles to the widespread adoption of
the new CLSI breakpoints. However, the FDA has started this ratification process by
releasing guidance that informs pharmaceutical companies and manufacturers of the
need to review their drug package information and revise them to meet current drug
testing criteria (Food and Drug Adminstration, 2009). Unfortunately, this problem may
persist for some time, because the regulatory system by which the FDA updates or
modifies drug labels and information can move slowly (Paxton, 2010). Until the FDA
approves the new CLSI breakpoints for AST system manufacturers, inadequate
surveillance and control of CRE will continue to pose a problem. In the meantime, it is
recommended that institutions and clinical laboratories adopt the new CLSI criteria if
they can conduct an in-house confirmatory susceptibility testing (Paxton, 2010).
Relevance to Public Health
CREs and KPCs are particularly important in public health because of the high
mortality associated with their infections and the tendency to spread beyond health
centers (Bratu et al., 2005; Patel, Huprikar, Factor, Jenkins, & Calfee, 2008). In terms of
cost of treatment, an estimated $21 billion - $34 billion are spent annually in the
treatment of CREs in the U.S. (Spellberg et al., 2011).
Some major risk factors for acquiring CRE are exposure in health care facilities,
erratic use of antibiotics, a history of recent organ transplant (including stem-cell
transplantation), the use of mechanical ventilation and longer hospital stay. These risks
are also independently associated with higher mortality due to CREs (Patel et al., 2008).

Other risk factors associated with higher mortality among patients with CRE infections
include deteriorating health status, intensive care unit admission, and the use of
invasive medical instrumentation, etc., (Falagas et al., 2007; Schwaber et al., 2008). A
mortality rate of 48% has been reported among patients with CRE infections, and a
crude mortality rate as high as 71.9% has been reported by some researchers (Patel et
al., 2008).
There is a high potential for extensive spread of the carbapenem resistance gene
from one Enterobacteriaceae into another within a health institution or to the
community through mobile transmissible genetic components on the KPC gene
(Watanabe, Iyobe, Inoue, & Mitsuhashi, 1991; Yigit et al., 2001). CREs are mainly seen in
long term acute care (LTAC) centers. This suggests that LTACs could be a potential
reservoir for CREs (Perez et al., 2010). Although the focus of CRE prevention has been
on acute care settings (long and short term), there have been documented cases of
CREs in non-acute care settings, for example, in long term care facilities, such as nursing
homes and assisted living facilities (Urban et al., 2008). Therefore, limiting prevention
and control efforts to acute care centers might be counterproductive.
CREs are not a problem limited to individual facilities. They can affect entire
communities and nations, which highlights the role of public health in this issue. Public
health organizations have the capacity to reach across all care institutions and to
improve community situational awareness with regards to CREs and coordination of
prevention efforts. For example, in Israel, a centrally coordinated effort by the Israel

Carbapenem-Resistant Enterobacteriaceae Working group has been helpful in
decreasing the incidence of CREs (Schwaber et al., 2011).
The implementation of the new CLSI’s MIC guidelines and breakpoints can have a
significant impact on carbapenem AST reports from clinical diagnostic laboratories, with
associated alterations in antibiotic prescription by clinicians (MacKenzie et al., 2007).
Therefore, accurate laboratory information, better knowledge of the patient’s history,
and current information about CREs are all necessary to avoid uncertainties in
carbapenem AST reports (Endimiani et al., 2009).
In Nevada, data are needed to determine the percentage of isolates with
carbapenem MIC from the current CLSI breakpoints that are truly resistant to
carbapenems, by the presence of the resistant KPC gene (Endimiani et al., 2009). The
objectives of this study were to determine the presence of the KPC gene and the
carbapenem antimicrobial resistance profiles of clinical isolates from health care
facilities in Nevada for the purpose of determining if there is a difference in the rate of
resistance between the previous and the current CLSI criteria.

RESEARCH QUESTIONS
1. What is the percentage of CRE isolates that are positive for the KPC gene using the
current CLSI criteria for resistance to carbapenems?
2. What is the mechanism of resistance seen in CRE isolates?
3. Is there a benefit in adopting the new CLSI carbapenem guidelines?

HYPOTHESES
Ho1: There is no difference between carbapenem resistance in clinical isolates with the
previous breakpoints and the current breakpoints.
HA1: There is a difference between carbapenem resistance in clinical isolates with the
previous breakpoints and the current breakpoints.

Ho2: There is no difference in carbapenem susceptibility profiles among KPC gene
positive isolates between the current and the previous CLSI breakpoints.
HA2: There is a difference in carbapenem susceptibility profiles among KPC gene positive
isolates between the current and the previous CLSI breakpoints.

MATERIALS AND METHODS
Test Organisms
Pure cultures from clinical isolates suspected of being carbapenem-resistant
Enterobacteriaceae (de-identified of patient data) were obtained from Quest
Diagnostics in Las Vegas, Nevada, and were transported to the Emerging Diseases
Laboratory (EDL) at the University of Nevada, Las Vegas, for analysis. Enterobacteriaceae
strains were obtained from the American Type Culture Collection (ATCC, Manassas, VA),
and were used as quality control (QC) organisms. Two of these ATCC organisms are
carbapenem resistant and possess the KPC gene, while four of these strains are
susceptible to carbapenems and do not possess the KPC gene (Table 2).

Table 2: Test Organisms Obtained from the American Type Culture Collection (ATCC).
Test Organism

ATCC#

blaKPC gene

Klebsiella pneumoniae
Klebsiella pneumoniae
Klebsiella pneumoniae
Klebsiella pneumoniae
Klebsiella pneumoniae
Enterobacter hormaechi

13883
4352
700603
BAA 1706
BAA 1705
BAA 2082

Negative
Negative
Negative
Negative
Positive
Positive

Lyophilized ATCC strains were re-suspended in nuclease-free water (HyClone
Laboratories, Logan, Utah), vortexed, and cultured on Tryptic Soy Agar (TSA) (Becton
Dickinson, Sparks, MD). All clinical isolates were stored at 4°C upon arrival and restreaked onto fresh TSA plates (Becton Dickinson) within 48 hours of receipt. QC
organisms and clinical isolates were incubated at 35°C in ambient air for 24-48 hours.
Isolated colonies were picked and used to prepare freezer and refrigerator stocks.
Freezer stocks were prepared by transferring two to three isolated colonies to a
2 ml cryogenic tube containing 500 l of Tryptic Soy Broth ( Becton Dickinson) and 500
l of sterile glycerol (MP Biomedicals, Solon, Ohio). The tube was vortexed vigorously
for 30 seconds or until the colonies were completely re-suspended, followed by
incubation in a rotary shaker at 35°C for 30 minutes and 175 rpm. Freezer stocks were
stored at -70°C. Refrigerator stocks were prepared by re-streaking an isolated colony
from the 24-48 hours TSA plate onto a TSA slant (Becton Dickinson), incubated
overnight at 35°C ambient air, and stored at 4°C.
Two to three isolated colonies from the 24-48 hours TSA plate were transferred
to a micro-centrifuge tube containing 400 l of nuclease free water (HyClone

Laboratories). The suspension was vortexed for 15 – 30 seconds for proper
homogenization, and stored at -70°C for DNA extraction.
DNA Extraction
Bacterial DNA was extracted using the MoBio PowerSoil DNA extraction kit
(MoBio, Carlsbad, CA) according to the manufacturer’s instructions with one exception;
200 μl of sample (instead of 0.25g) was used for extraction. The DNA extract was eluted
in 100 μl of the C6 buffer solution provided, and stored at –70°C until ready for use.
Template DNA Concentration
After DNA extraction, the amount of DNA in each sample extract was measured
with a Spectronic TM Genesys 10 BIO UV- Visible spectrophotometer (Thermo Fisher
Scientific, Madison, WI) using the nanoCell accessory – 0.2mm path length. Briefly, 1.0
µl of the sample extract was used, after zeroing the spectrophotometer with the C6
solution from the PowerSoil DNA extraction kit. The absorbance was set at 260/280 nm,
with 320 nm reference wavelength and 2500 dilution factor. Samples were measured in
duplicate and DNA concentrations were expressed in ng/µl. All samples with DNA
concentration of 21 ng/µl and above were diluted using Tris-EDTA (TE) buffer (Teknova,
Hollister, CA) prior to the PCR assay. This enabled the DNA in the PCR to maintain a
concentration between 10 – 100 ng (Life Technologies).
Real-Time Polymerase Chain Reaction (PCR)
The 7900 HT Fast PCR System (Applied Biosystems, Foster City, CA) was used for
detection and amplification of the blaKPC gene. Primers and a fluorescent probe specific
for the blaKPC gene were identified from the literature that produced a 246-bp

amplicon (Hindiyeh et al., 2008; Tenover et al., 2006). The master mix was prepared
using TaqMan 1X Universal Master Mix (Branchburg, New Jersey), sterile Nuclease Free
Water (Promega, Madison, WI), 0.3 µM of forward primer - 5’-GAT ACC ACG TTC CGT
CTG G-3’ (Hindiyeh et al., 2008), 0.3 µM of reverse primer - 5’-GCA GGT TCC GGT TTT
GTC TC-3’ (Tenover et al., 2006), and 0.2 µM of probe -6-carboxyfluorescein-5’-AGC
GGC AGC AGT TTG TTG ATT G-3’-6 carboxytetramethylrhodamine (Hindiyeh et al.,
2008). Primers were obtained from Eurofins MWG Operon (Huntsville, AL), and the
probe was obtained from Life Technologies.
All PCR assay reactions were performed in duplicate, using a total volume of 25
µl, containing 5 µl of template DNA (i.e., 10-100 ng) and 20 µl of the master mix
solution. Positive and negative controls were included with each PCR assay. Following
amplification, the results were analyzed on the PCR computer using the SDS ver. 3.0
software. Once amplification was completed, the level of amplification was reported by
the software as the mean Cycle Threshold (CT) value of replicate samples. CT refers to
the PCR cycle at which fluorescence (i.e., amplification product) is first detected. A
sample was considered positive by real-time PCR and possessed the blaKPC gene, if the
CT crossed the threshold before the threshold cycle of 40. A CT value of 40 or
undetermined represents no target DNA present. Samples that tested undetermined for
the blaKPC gene were re-analyzed using an Internal Positive Control (IPC) (Life
Technologies) to determine if there were inhibitors present in the reaction.

Internal Positive Control
A commercially available TaqMan exogenous Internal Positive Control (Life
Technologies) was used to detect PCR inhibition and rule out false negatives. The kit
included 10X Exogenous IPC Primer and Probe (VIC™ Probe) mix, 10X Exogenous IPC
Blocking Reagent, and 50X Exogenous IPC DNA. The blaKPC PCR assay was run with the
internal positive control; thus, absence or a decrease in amplification of the IPC DNA in
each duplex PCR indicated the presence of PCR inhibitors. Several dilutions (i.e., 10-1 to
10-3) of selected DNA samples were tested, to determine and eliminate potential PCR
inhibitors.
Antimicrobial Susceptibility Testing (AST) and Microbial Identification
All clinical isolates were subjected to carbapenem Antibiotic Susceptibility
Testing (AST) using gram-negative (GN) AST and identification cards for the Vitek 2
Compact system (bioMerieux, Durham, NC) following the manufacturer’s protocol. ASTGN69 and AST- XN06 Vitek 2 Gram negative cards were used for AST, and for microbial
identification, Vitek 2 GN ID card ref. 21341 was used (Appendices A and B). Briefly, the
clinical isolates were sub-cultured (from the refrigerator stocks or from the freezer
when there was no growth) onto TSA and incubated for 18-24 hours at 35°C in ambient
air. A cell suspension of each sample with optical density of 0.5 – 0.63 McFarland
Standard was prepared. The suspension was loaded onto the ID and AST cards in the
biological safety cabinet, and then transferred to the Vitek 2 Compact machine for
analysis. The results of the susceptibility profile were analyzed on the Vitek 2 system
computer using software version 5.04 (bioMerieux) according to the U.S. Food and Drug

Administration (FDA) (previous CLSI breakpoints) and the Current CLSI carbapenem
susceptibility breakpoints (Table 1). Furthermore, the Advanced Expert Analysis (AES)
was applied to our analysis to determine the phenotype of carbapenem resistance
implicated in our isolates. AES uses the knowledge base of the Vitek 2 system ver. 5.04
to determine resistance profile, resistance phenotype, and therapeutic interpretation of
the results. AES uses all information available rather than MIC values alone to determine
resistance. In some cases, isolates may have susceptible MIC yet be classified as nonsusceptible by AES.
Statistical Analysis
Results were analyzed to determine if there was any significant difference
between carbapenem susceptibility and non-susceptibility among individual antibiotics
when using the previous and the current CLSI breakpoint criteria. We also determined if
there was a statistically significant difference between the carbapenem susceptibility
profiles among blaKPC gene positive isolates when using the previous and the current
breakpoints. For our data, a non-parametric analysis (i.e., the Fisher Exact Test) was
used. All analyses were conducted using SPSS ver. 22.0 (IBM, Armonk, New York).

RESULTS
Test Organisms
Fifty-six isolates were received and sub-cultured on TSA, and incubated for 24-48
hours. Of these, one did not grow after various attempts to culture it. Two additional

isolates had the same identification number; therefore, one of these was not analyzed.
In total, 54 out of 56 isolates received were included in our analysis. These isolates
were recovered from urine (catheter, and clean catch; n=27), sputum (n=16), bronchiole
(n=1), wound (n=5), abscess (n=1), blood (n=2), abdominal fluid (n=1), and unspecified
location (n=3).
Template DNA Concentration
The amount of DNA present in 100 µl of each DNA extract was measured after
DNA extraction. The mean DNA concentration of all of the isolates from duplicate
measurements varied from 8.8 ng/l to 131.3 ng/l (Table 3). Subsequently, all DNA
extracts with a concentration greater than 21 ng/l were diluted. The final DNA
concentration in 5 µl of sample used for the PCR assay ranged from 10.7 ng to 94.0 ng.
The UV- Visible spectrophotometer determines the DNA concentration by using
the ratio of DNA absorption at 260 nm to absorption of RNA at 280 nm. The average
260/280 absorption ratio measured ranged from 0.033 to 8.188 (Table 3).
Real- Time Polymerase Chain Reaction (PCR) Analysis
All isolates with mean CT values <40 were regarded as positive, and thus
considered to harbor the blaKPC gene. Known KPC gene negative ATCC strains (i.e., K.
pneumoniae ATCC 13883, K. pneumoniae ATCC 4352, K. pneumoniae ATCC BAA 1706,
and K. pneumoniae ATCC 700603) all tested PCR negative (undetermined) for the
presence of the blaKPC gene (Table 3). All known KPC gene positive strains obtained
from ATCC (i.e., Enterobacter hormaechei ATCC BAA 2082 and Klebsiella pneumoniae

ATCC BAA 1705) tested positive for the KPC gene with mean CT values of 17.1 and 18.8,
respectively (Table 3).
Ten out of 54 isolates produced undetermined (i.e., negative) results with PCR
and were regarded as negative for the blaKPC gene. Additional PCR analyses performed
with the Internal Positive Control (IPC) on isolates that were negative showed inhibition
in several blaKPC gene negative isolates. Subsequently, serial dilution (1:10 and 1:100)
of the inhibited samples resulted in a positive blaKPC gene by PCR (Table 4). The
prevalence rate of blaKPC gene among 54 suspected CRE isolates received from Quest
Diagnostics in Las Vegas was 83.3%, and the prevalence of the blaKPC gene among
Klebsiella pneumoniae isolates (identified with the Vitek 2 Compact instrument) was
93.6%.

Table 4: Internal Positive Control (IPC) PCR Results of blaKPC Gene Negative Isolates
Sample

NTC
Klebsiella pneumoniae
ATCC BAA 1705

CRE 004

CRE 021
CRE 029

CRE 033
CRE 036
CRE 039
CRE 040
CRE 042

CRE 050
CRE 052
NTC = No Template Control

Dilution

blaKPC
(Mean Ct Value; n=2)

IPC
(Mean Ct; n=2)

N/A

undetermined

31.85

1:10

18.80

undetermined

1:100

22.53

undetermined

1:1000

26.85

32.11

Undiluted

undetermined

undetermined

1:10

undetermined

32.68

1:100

undetermined

32.66

1:10

undetermined

31.31

Undiluted

undetermined

undetermined

1:10

undetermined

32.34

1:100

undetermined

31.74

Undiluted

undetermined

34.07

1:10

undetermined

32.20

1:10

undetermined

30.90

Undiluted

undetermined

33.53

1:10

undetermined

31.99

1:10

undetermined

31.12

Undiluted

undetermined

undetermined

1:10

22.02

undetermined

1:100

25.79

35.26

1:10

undetermined

32.07

1:100

undetermined

31.84

1:10

undetermined

31.50

Identification of Isolates
Microbial identification carried out on CRE isolates using the Vitek 2 ID card No.
21341 identified the following organisms with at least 94% confidence (Table 5):
Klebsiella pneumonia pneumoniae (n=46), Escherichia coli (n=2), Enterobacter aerogenes
(n=2), Citrobacter freundii (n=2), Acinetobacter baumannii (n=1), and Proteus mirabilis
(n=1).

Table 5: Organisms Identified by Vitek 2 ID Analysis.

Organisms Identified

N

Acinetobacter baumannii
Citrobacter freundii
Klebsiella pneumoniae
Proteus mirabilis
Enterobacter aerogenes
Escherichia coli

1
2
46
1
2
2

Antibiotic Susceptibility Testing (AST)
The Vitek 2 instrument was used for AST of ATCC reference samples and CRE
isolates, and these were analyzed using the current and the previous CLSI MIC
breakpoints. Our reference samples included three known KPC negative species from
ATCC (Klebsiella pneumoniae ATCC 13883, Klebsiella pneumoniae ATCC 4352, and
Klebsiella pneumoniae ATCC 700603), and two known KPC positive species (Enterobacter
hormaechei ATCC BAA 2082 and Klebsiella pneumoniae ATCC BAA 1705). Carbapenem
non-susceptibility (i.e., resistance) was concluded for all samples with intermediate or
resistant MIC results. Analysis of the ATCC negative reference samples using both

criteria (previous and current CLSI breakpoints), showed susceptibility to all
carbapenems. All KPC positive ATCC controls were non-susceptible to all carbapenems
(Table 6).

Table 6: ATCC blaKPC Positive and Negative Organisms and their AST Results.
CLSI Criteriaa
2009 2012 2009 2012
Imipenem
Doripenem

2009 2012
2009 2012
Test Organism
Ertapenem
Meropenem
K. pneumoniae
S
S
S
S
S
S
S
S
ATCC 13883
K. pneumoniae
S
S
S
S
S
S
S
S
ATCC 4352
K. pneumoniae
S
S
S
S
S
S
S
S
ATCC 700603
E. hormaechi
R
R
I
R
nd
R
R
R
ATCC BAA 2082
K. pneumoniae
R
R
R
R
nd
R
R
R
ATCC BAA 1705
ATCC- American Type Culture Collection; S = Susceptible; I = Intermediate; R= Resistant; nd = no
criteria available for 2009.
a

2009 represents previous criteria and 2012 represents current criteria.

Ertapenem Susceptibility Testing
According to the Vitek 2, Ertapenem use was not indicated for clinical use in one
of our 54 CRE isolates. This resulted in 53 isolates that were analyzed with the previous
and current CLSI criteria for this antibiotic. Using current breakpoints (CLSI M100-S22)
for susceptibility interpretations, 48 of our 53 isolates (90.6%) showed resistance (i.e.,
non-susceptibility) to Ertapenem, and 5 isolates (9.4%) were susceptible for this
antibiotic (Table 7). However, when using the previous breakpoints (CLSI M100-S19), 47
isolates (88.7%) were resistant and 6 isolates (11.3%) were susceptible to Ertapenem.

Transitioning to the current CLSI criteria for this antibiotic would result in a change in
resistance rate from 88.7% to 90.6%.
Imipenem Susceptibility Testing
Using the current Imipenem breakpoints, 49 of 54 isolates (90.7%) were
classified as resistant, and five isolates (9.3%) were classified as susceptible (Table 7). In
terms of the previous breakpoints, Imipenem resistance occurred in 46 of 54 isolates
(85.2%), with 8 isolates (14.8%) classified as susceptible. Transitioning to the current
CLSI criteria for Imipenem would result in a change in resistance rate from 85.2% to
90.7%.
Doripenem Susceptibility Testing
According to the Vitek 2, Doripenem was not indicated for clinical use in two of
our 54 CRE isolates. This resulted in 52 isolates that were analyzed with the previous
and current CLSI criteria for this antibiotic. Doripenem MIC interpretations with the
current breakpoints classified 47 of 52 isolates (90.4%) as non-susceptible and 5 isolates
(9.6%) as resistant (Table 7). Doripenem is a fairly new carbapenem antibiotic;
therefore, there were no susceptibility interpretations published for it in the previous
CLSI breakpoints. Thus, we cannot make a comparison between the previous and
current carbapenem breakpoints.
Meropenem Susceptibility Testing
For Meropenem, resistance was reported in 49 of 54 isolates (90.7%) when using
the current CLSI breakpoints, but with the previous breakpoints Meropenem resistance
was reported in 47 of 54 (87.0%) isolates, with 7 isolates (13.0%) showing susceptible to

this antibiotic (Table 7). Transitioning to the current CLSI criteria for Meropenem would
result in a change in resistance rates from 87.0% to 90.7%.

Table 7: Individual Carbapenem Susceptibility Among all CRE Isolates Analyzed.
Previous Breakpoints
(M100-S19)
Individual
carbapenems

Susceptible

Current Breakpoints
(M100-S22)

Non-susceptible

Susceptible

Nonsusceptible

N

%

N

%

N

%

N

%

Ertapenema

6

11.3

47

88.7

5

9.4

48

90.6

Imipenem

8

14.8

46

85.2

5

9.3

49

90.7

Doripenemb

nd

nd

nd

nd

5

9.6

47

90.4

Meropenem

7

13.0

47

87.0

5

9.3

49

90.7

a

b

Ertapenem use was not indicated for 1 isolate. Doripenem use was not indicated for 2
isolates. nd = Doripenem interpretation was not defined in the Previous Breakpoints.

Ertapenem Susceptibility of blaKPC Gene Negative Isolates
Of the nine CRE isolates that were negative for the blaKPC gene, the Vitek 2
analysis indicated that eight of these should have been treated with Ertapenem (Table
8). When using the previous breakpoints, six of these isolates were susceptible to
Ertapenem (i.e., two isolates were non-susceptible or resistant). When the MICs were
analyzed with the current breakpoints, five were classified as susceptible to Ertapenem
and three as resistant. Therefore, there was only one blaKPC gene negative isolate
which reported susceptibility to Ertapenem with the previous criteria, but changed to
resistant with the current criteria (Table 9).

Imipenem Susceptibility of blaKPC Gene Negative and Positive Isolates
All nine of the blaKPC gene negative isolates were indicated for treatment with
Imipenem. When analyzed with the previous CLSI criteria, seven isolates were classified
as susceptible to Imipenem, while two isolates were resistant (Table 8). With the current
breakpoints, five of the nine isolates were susceptible to Imipenem, while four were
resistant. Transitioning to the current CLSI criteria would result in two blaKPC gene
negative isolates previously reported as susceptible for Imipenem that now would be
reported as resistant with the current breakpoints (Table 9). On the other hand, only
one blaKPC gene positive that was susceptible to Imipenem when using the previous
breakpoints changed to resistant with the current breakpoints (Table 9).

Table 8: Individual Carbapenem Susceptibility Among blaKPC Gene Negative Isolates.
Previous Breakpoints
Current Breakpoints
(M100-S19)
(M100-S22)
NonNonSusceptible
Susceptible
Susceptible
Susceptible
3
Ertapenem
6
2
5
4
Imipenem
7
2
5
3
Doripenem
nd
nd
4
4
Meropenem
7
2
5
nd = Doripenem interpretation was not defined in the previous breakpoints

Individual
carbapenems

Table 9: Susceptibility Changes (Susceptible to Non-Susceptible) Between the Previous CLSI
Criteria and the Current Criteria Among blaKPC Genes (Negative and Positive).
Individual
carbapenemsa

blaKPC Gene
Negative

blaKPC Gene
Positive

Ertapenem

1

0

Total number
of changes
1

Imipenem

2

1

3

0

2

Meropenem
2
a
Doripenem susceptibilities were not compared.

Doripenem Susceptibility of blaKPC Gene Negative Isolates
For blaKPC gene negative isolates that were indicated for treatment with
Doripenem (n= 7), analysis with the current CLSI breakpoints reported only four isolates
as susceptible to Doripenem while three were resistant (Table 8). We cannot make a
comparison between the previous and current breakpoints for this antibiotic because
there were no susceptibility interpretations published for it in the previous CLSI
breakpoints (Table 9).
Meropenem Susceptibility of blaKPC Gene Negative Isolates
When using the previous breakpoints, Meropenem susceptibility was seen in
seven of nine blaKPC gene negative isolates, while two isolates were resistant to this
antibiotic (Table 8). With the current breakpoints, five isolates were susceptible to
Meropenem, and four were resistant. Transitioning to the new CLSI criteria would
result in two blaKPC gene negative isolates previously reported as susceptible to
Meropenem that now would be reported as resistant with the current breakpoints
(Table 9).
Carbapenem Susceptibility of blaKPC Gene Positive Isolates
Among blaKPC gene positive isolates, individual carbapenem susceptibility
profiles did not vary much between the previous criteria and the current CLSI criteria
(Table 10). All blaKPC gene positive isolates (n=45) reported resistance to Ertapenem
and Meropenem across the two criteria. Thus, non-susceptibility rate among blaKPC
gene positive isolates continued to be the same at 100% for Ertapenem and
Meropenem, when using the previous and current criteria. However, Imipenem showed

a change in resistance rate from 97% to 100% when comparing the previous to the
current CLSI criteria (Table 10). No data comparisons were possible for Doripenem;
however, the blaKPC gene positive isolates showed a resistance rate of 98% for this
antibiotic (with the current criteria) (Table 10).

Table 10: Individual Carbapenem Non-Susceptibility in blaKPC Gene Positive Isolates (n= 45).
Individual
carbapenems

Previous Breakpoints
(M100-S19)
Susceptible

Non-Susceptible

Current Breakpoints
(M100-S22)
Susceptible

Non-Susceptible

Ertapenem
0
45 (100%)
0
Imipenem
1
44 (97.8%)
0
Doripenem
nd
nd
1
Meropenem
0
45 (100%)
0
nd = Doripenem interpretation was not defined in the previous breakpoints

45 (100%)
45 (100%)
44 (97.8%)
45 (100%)

Mechanisms of Antibiotic Resistance
Many isolates reported different and more than one resistance phenotype when
the Expert Analysis (AES) from the Vitek 2 instrument was applied to our AST analysis.
The resistance phenotypes (or mechanism of resistance) reported for all isolates were
different depending on the AST card used (Table 8). Analysis with the GN 69 AST card
reported the following resistance phenotypes for our isolates: Extended Spectrum BetaLactamase (ESBL), Impermeability (carbapenems and cephamycins), carbapenemase
(Metallo- or KPC), Penicillinase (acquired or wild type), and High Level AmpC (HL-CASE)
(Table 11).
Analysis with the GN XN 06 AST card showed the following resistance
phenotypes: ESBL, Impermeability (carbapenems and cephamycins), carbapenemase

(Metallo- or KPC), Inhibitor Resistant PASE (IRT or OXA), Penicillinase, and High Level
AmpC (Table 11). Regardless of the AST card used, the three most common resistance
mechanisms observed were: ESBL (87%), Impermeability (85.2%), and carbapenemase
(83.3%).

Table 11: Carbapenem Resistance Phenotypes Implicated in all Isolates (n=54).

Carbapenem Resistance Phenotypea
Extended Spectrum Beta- lactamase
Impermeability (carbapenems and cephamycins)
Carbapenemase (Metallo- or KPC)
Penicillinase (acquired or wild type)
High Level AmpC (HL-CASE)
Inhibitor Resistant PASE (IRT or OXA)
a

GN 69 AST Card
(N; percentage)
47 (87.0%)
46 (85.2%)
45 (83.3%)
2 (3.7%)
2 (3.7%)
0 (0%)

GN XN 06 AST
Card (N;
percentage)
47 (87.0%)
48 (88.8%)
49 (90.7%)
1 (1.9%)
1 (1.9%)
1(1.9%)

Most isolates exhibited more than one phenotype.

The nine isolates that were negative for the blaKPC gene were identified (Table
12). According to the Vitek 2 Advanced Expert Setting Analysis (AES), resistance
phenotypes for these isolates were ESBL, Impermeability, carbapenemase (Metallo- or
KPC), Penicillinase (acquired or wild type), High Level-Case (amps), and Inhibitor
Resistant PASE (IRT or OXA) (Table 12).

Table 12: Carbapenem Resistance Phenotype Implicated in all blaKPC Negative Isolates.
Organisms ID
Acinetobacter baumannii
Citrobacter freundii

N

Resistance Phenotype (GN 69/XN 06 AST Card)

1
1

Impermeability
carbapenemase (Metallo- or KPC)
Penicillinase, Inhibitor Resistant PASE (IRT or OXA), ESBL,
Klebsiella pneumoniae
3
Impermeability
Proteus mirabilis
1
ESBL/carbapenemase (Metallo- or KPC)
ESBL/HL-Case (AmpC)a, Impermeability, carbapenemase
Enterobacter aerogenes
2
(Metallo- or KPC)
1
Escherichia coli
Penicillinase/ Inhibitor Resistant PASE (IRT or OXA)
a
HL-Case (AmpC) – High Level AmpC

Isolates that Changed from Susceptible to Non-Susceptible Between 2009 and 2012
Breakpoints
Five isolates changed from susceptible to non-susceptible in at least one carbapenem
when using the current criteria. Four of these where blaKPC gene negative (Table 13).
Carbapenemase (Metallo- or KPC) were implicated as the mechanism of resistance in
four of these. Other resistance mechanisms implicated included ESBL, AmpC, and
Impermeability. Specifically these isolates included three non-Klebsiella species and two
Klebsiella pneumoniae.

Table 13: List of Isolates that Changed in AST Between the Previous and the Current Breakpoints
Isolates
CRE 021
CRE 033
CRE 050
CRE 052
CRE 053

Organism ID
Citrobacter
freundii
Proteus
mirabilis
Enterobacter
aerogenes
Klebsiella
pneumoniae
Klebsiella
pneumoniae

blaKPC
status

Negative

Carbapenem
implicated
AES Resistance Phenotypes
Imipenem,
Meropenem Carbapenemase (Metallo- or KPC)
ESBL, Carbapenemase (Metallo-or
Meropenem KPC)
AmpC, Impermeability,
Imipenem
Carbapenemase (Metallo-or KPC)

Negative

Ertapenem

Positive

Ertapenem

Negative
Negative

ESBL, Impermeability
ESBL, Impermeability,
Carbapenemase (Metallo- or KPC)

Susceptibility to other Antibiotics
In our study, susceptibility of CRE to gentamicin, ceftazoxime and cefepime were
relatively high at 57%, 44% and 41%, respectively.

Statistical Analysis
Results were analyzed to determine if there was any significant difference
between carbapenem susceptibility and non-susceptibility among individual antibiotics
when using the previous and the current breakpoint criteria. Statistical analysis using
Fisher’s Exact Test on AST with the previous and current criteria for Ertapenem,
Imipenem, and Meropenem were not significantly different (p-values > 0.05). Therefore,
we failed to reject the null hypothesis (H01) of equal proportion in carbapenem
resistance between the previous and the current CLSI breakpoint criteria.
Statistical analysis to determine if there was a significant difference between the
carbapenem susceptibility profiles among isolates with the blaKPC gene when using the
previous and the current breakpoints were not significantly different (p-values > 0.05).

We failed to reject the null hypothesis (Ho2) that there is no difference in carbapenem
susceptibility profiles among KPC gene positive isolates between the current and the
previous CLSI breakpoints.

DISCUSSION
In 2012, the Clinical and Laboratory Standards Institute (CLSI) published updated
editions of its antimicrobial susceptibility testing (AST) standards. The updated criteria
are intended to detect emerging bacterial resistance. Periodic updates of these
guidelines are necessary because bacteria acquire resistance to antibiotics over time,
and using the most current knowledge ensures that infections are treated consistently
and fosters good antibiotic stewardship. In recent times, automated AST systems have
become the most common method of conducting susceptibility testing; these
instruments measure the minimal inhibitory concentration of antibiotics using the CLSI
guidelines. The FDA considers non-susceptibility to antibiotics as MIC results that are
intermediate or resistant according to fixed breakpoints; in addition, the agency is
responsible for approving the use of CLSI criteria with automated AST systems. The
lower MIC for carbapenem antibiotics established for KPCs in 2012 by the CLSI have not
been endorsed by the FDA. Therefore, data were needed to estimate the percentage of
clinical isolates that are potentially resistant to carbapenems by determining the
presence of the KPC gene. Detecting the presence of the KPC gene is important because,
the use of carbapenems determined by using the current breakpoints for infections may

have poor clinical outcomes if the gene is present. Conversely, if the KPC gene is absent,
treatment with carbapenems may still be indicated. The objectives of this study were to
determine carbapenem AST profiles, resistance rates based on the previous and current
CLSI criteria, and the presence of the KPC gene in CRE isolates.
In this study, carbapenem resistance among CRE isolates was mainly seen among
Klebsiella pneumoniae (87%), followed by E. coli, Enterobacter aerogenes, and
Citrobacter freundii, each with 3.7%. Acinetobacter baumannii and Proteus mirabillis
(1.9% each) were also identified in our study as being resistant to carbapenems. Our
results are similar to other published articles on CREs in which Klebsiella spp. are the
most commonly reported Enterobacteriaceae with non-susceptibility to carbapenems.
In a study by Jacob et al. (2013), the most commonly reported organism among 72 CRE
isolates were Klebsiella species (n=49), with Enterobacter species and E. coli contributing
14 and 10 isolates, respectively (Jacob et al., 2013). We also observed that urine
samples (27 out of 54) were the most common site of CRE isolation, followed closely by
respiratory isolates (17 out of 54). Jacob et al. also identified CREs in urine samples more
frequently (89%) than in other sites.
The prevalence rate of the blaKPC gene was 83.3% among suspected CRE isolates
from different healthcare centers in Nevada, determined in our study. Isolates identified
as Klebsiella pneumoniae comprised the majority of our CRE isolates, and 93.6% of these
had the blaKPC gene. These rates and findings are similar to other studies in the U.S.
that reported the blaKPC gene as the most commonly implicated gene in carbapenem
resistance among the Enterobacteriaceae (Deshpande, Rhomberg, Sader, & Jones,

2006). Also, the prevalence of the blaKPC gene among Klebsiella pneumoniae identified
in our study was similar to that reported in other studies published in the U.S., and
abroad (Nordmann, Cuzon, & Naas, 2009). A study (Shanmugam, Meenakshisundaram,
& Jayaraman, 2013) in India reported a blaKPC gene prevalence rate of 67.4% among
CREs, and other recent studies have reported a blaKPC gene prevalence between 82%
and 100% (Mosca et al., 2013; Raghunathan, Samuel, & Tibbetts, 2011; Shanmugam et
al., 2013). Although CREs have been recently reported in Nevada, to our knowledge, this
is the first published report of prevalence of KPC-producing Enterobacteriaceae isolated
from patients in southern Nevada.
The CLSI and the Centers for Disease Control and Prevention recommend that
CRE isolates with antibiotic resistant profiles or elevated, but susceptible profiles, be
confirmed with the Modified Hodge Test (Clinical and Laboratory Standards Institute,
2009). While the Modified Hodge Test has deficiencies, it has remained the first step in
detecting carbapenemase activity in clinical isolates in many facilities for isolates with
elevated MIC, and thus, it is particularly important as part of an early infection control
program. In this study, we used a PCR-based assay as an alternative to verify
carbapenem resistance among CRE isolates.
The recently published CLSI standards for carbapenems have been met with
mixed reception. Some researchers have argued that the change may only increase the
false positive results in AST analysis, and thus lead to unnecessary and expensive
treatments (Po-Yu Liu et al., 2014). In our study, we found no difference between
carbapenem resistance in clinical isolates with the previous and the current breakpoints.

Also, there was no difference between susceptibility profiles among blaKPC gene
positive isolates when using the two criteria. Therefore, we conclude that the current
CLSI criteria may not offer additional benefit in the fight against CREs. Our results are
similar to others reported in the literature that showed either no change between the
two breakpoints or unnecessary increase in the estimation of carbapenem resistance
(Hombach, Bloemberg, & Bottger, 2012; Metwally, Gomaa, Attallah, & Kamel, 2013).
We used the Expert Analysis (AES) available with our automated AST instrument
to determine the resistance phenotype of isolates that tested negative for the blaKPC
gene, yet tested non-susceptible (resistant) to carbapenems during our AST analysis.
The AES reported Impermeability, carbapenemase (metallo- or KPC), ESBL, and HL-Case
(AmpC), as the commonly involved mechanisms of resistance among blaKPC gene
negative isolates using both the previous and current criteria. Impermeability is the
inability of an antibiotic to penetrate the cell wall of the organism. Carbapenemases
and Extended Spectrum β-lactamases (ESBL) work by hydrolyzing the β-lactam structure
of the antibiotic (David L Paterson & Bonomo, 2005). While ESBL do not hydrolyze
carbapenems and cephamycins, carbapenemases hydrolyze all groups of -lactams.
High Level Case (HL-Case) AmpC’s mechanism of resistance involves hydrolysis of βlactams, especially cephalosporin through a plasmid mediated cephalosporinase
(George A Jacoby, 2009). Because our PCR assay was designed to detect only the blaKPC
gene, it is possible that Metallo-beta-lactamase (MBL) may still be involved in isolates
with carbapenemase (metallo- or KPC) phenotypes. The MBL is a less common
carbapenem resistance mechanism, but has been increasing in prevalence in recent

reports (Centers for Disease Control and Prevention, 2010; Rolain, Parola, & Cornaglia,
2010; Tijet et al., 2011).
Other carbapenem resistance phenotypes that we observed were
Impermeability and HL-Case (AmpC), and these were mainly seen in non-Klebsiella
pneumoniae organisms. These findings are in agreement with several published reports
showing that Impermeability and AmpC enzymes are carbapenem resistance
phenotypes commonly implicated in other Enterobacteriaceae such as Citrobacter spp.,
Enterobacter spp., and Proteus mirabilis (Mainardi et al., 1997; Mammeri, Nordmann,
Berkani, & Eb, 2008). Our study also supports that ESBL is commonly involved in
resistance mechanisms of CREs along with carbapenemase (Thomson, 2010).
Because the amount of antibiotics used on patients and the development of
resistance are directly proportional, increased reports of Enterobacteriaceae resistant to
carbapenems and reduced MIC breakpoints (current CLSI criteria) will increase the
number of Enterobacteriaceae determined to be resistant to at least one agent in any
antimicrobial category. Therefore, it is anticipated that clinicians and healthcare workers
will most likely prescribe increased doses of carbapenems or other antimicrobial classes
which may lead to more resistance (Magiorakos et al., 2012).
Infections caused by CREs are difficult to treat, but with early detection in
combination with prompt implementation of infection prevention and control practices,
the high morbidity and mortality rate associated with CREs may be reduced (Cohen et
al., 2011; Kochar et al., 2009). The CDC categorically recommend through their CRE
toolkit, an aggressive implementation of infection prevention and control strategies

once CREs are detected (Centers for Disease Control and Prevention, 2012b).
Prevention interventions, such as patient isolation, active surveillance cultures, patient
cohorting, and education, have been effective in decreasing the incidence of CREs
(Ciobotaro, Oved, Nadir, Bardenstein, & Zimhony, 2011; Debby Ben‐David et al., 2010).
In terms of chemotherapy, the limited treatment alternatives that exist for
patients with CRE infections include the use of combination therapies involving
carbapenems, tigeycline, colistin, amikacin, and polymixin (Castanheira et al., 2009;
Neuner et al., 2011). We determined that gentamicin, ceftizoxime and cefepime had
relatively high susceptibilities among CREs in our study. Whether or not these agents
demonstrate clinical success, especially in severe CRE infections, remains to be
determined in vivo (Nayman-Alpat et al., 2010). In-vitro combinations of these antibiotics
have shown bactericidal and synergistic effects (Bratu et al., 2005; Le, McKee, SrisuphaOlarn, & Burgess, 2011; Pankey & Ashcraft, 2011; Pournaras et al., 2011). However,
higher toxicity, side effects, limited efficacy, and concerns of spread of resistance have
limited their use in patients. Resistance to polymyxins and tigeycline or any known
alternative have also been reported in some case-series studies, and suggest a fresh
concern of pan-antibiotic resistance among CREs (Elemam, Rahimian, & Mandell, 2009).
Our study had several strengths and some limitations. The number of isolates
included in the study was limited; however, our pilot study did provide data that can be
utilized in further studies. Molecular detection of the blaKPC gene only detected isolates
that express the KPC gene and may have underestimated the presence of other
resistance mechanisms implicated in CREs, such as the MBL, the OXA, and the AmpC

enzymes in blaKPC gene negative isolates. Because Klebsiella pneumoniae
carbapenemase is the most implicated carbapenemase in the U.S., in a resource limited
setting, targeting the KPC gene will be a more efficient way to detect and confirm
carbapenem resistance. We did not perform the MHT as confirmation for
carbapenemase activity in our CRE isolates as recommended by the CDC; however, we
were able to use a PCR-based assay as an alternative to verify the Klebsiella pneumonia
carbapenemase gene.

CONCLUSIONS
Based on our findings, an understanding of the enzymatic mechanisms and other
phenotypes of resistance mediated by CREs is important in the prevention of these
organisms. Infections due to isolates that showed impermeability and concomitant
production of ESBLs may be managed with carbapenems if their MICs are in the
susceptible range. Although the implementation of the current CLSI breakpoints for
carbapenem AST can make results more comparable worldwide, especially if it
corresponds with the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) system. However, evidence-based studies should validate these revised
guideline changes before their general implementation. It is also important that
clinicians and laboratories are aware of the implications of the revised antibiotic
susceptibility testing reports in clinical practice, such as the effects on antibiotic
prescription and antibiotic stewardship. In addition, to ensure proper detection of

emerging resistance, species-related zones of inhibition or MIC breakpoints should be
published as a means to targeted control of CREs.
The results of this study are expected to provide health care providers and
infectious disease specialists an informed interpretation of susceptibilities and antibiotic
recommendations. It also serves as an important step towards developing targeted
strategies to control the spread of CREs in our communities. These results will help to
improve antibiotic stewardship in Nevada by determining the prevalence of the KPC
gene among CRE isolates from different health institutions in Las Vegas.
In conclusion, timely intervention, such as good infection control practices, rapid
detection, and prudent use of antibiotics will ensure that the spread of carbapenem
resistance among organisms is kept under control. Future studies should include a realtime PCR assay that is capable of detecting multiple resistance genes to provide rapid
and accurate detection of carbapenem resistance.

APPENDICES

Appendix A – Vitek 2 GN69 Card Information
Antibiotics tested
ESBL Confirmation Test
Ampicillin
Amoxicillin/
Clavulanic Acid
Ampicillin/Sulbactam
Piperacillin/Tazobactam
Cefazolin
Ceftazidime
Ceftriaxone
Cefepime
Ertapenem
Imipenem (new formula)
Gentamicin
Tobramycin
Ciprofloxacin
Levofloxacin
Nitrofurantoin
Trimethoprim/Sulfamethoxazole

Appendix B – Vitek 2 GN XN06 Card Information

Antibiotics tested
Ticarcillin/Clavulanic Acid
Piperacillin
Cefalotin
Cefuroxime
Cefuroxime Axetil
Cefotetan
Cefoxitin
Cefpodoxime
Cefotaxime
Ceftizoxime
Aztreonam
Doripenem
Meropenem
Amikacin
Nalidixic Acid
Moxiflaxacin
Norfloxacin
Tetracycline
Tigecycline

Table 3: DNA Concentrations and PCR Results for CRE Isolates.
Test Organism/Sample
Identification
Klebsiella pneumoniae
ATCC 13883
K. pneumoniae
ATCC 4352
K. pneumoniae
ATCC BAA 1706
K. pneumoniae
ATCC 700603
Enterobacter hormaechei
ATCC BAA 2082
K. pneumoniae
ATCC BAA 1705
CRE 001
CRE 002
CRE 003
CRE 004
CRE 005
CRE 006
CRE 007
CRE 008
CRE 009
CRE 010
CRE 011
CRE 012
CRE 013
CRE 014
CRE 015
CRE 016
CRE 017a
CRE 018
CRE 019a
CRE 020
CRE 021
CRE 022
CRE 023
CRE 024
CRE 025
CRE 026

Average
260/280
Ratio
(n=2)

Average
DNA Conc.
(ng/µl; n=2)

DNA
Conc. per
PCR rxn.

PCR Results
Mean CT
Value (n=2)

SD

1.929

33.8

16.9

undetermined

N/A

1.767

103.8

51.9

undetermined

N/A

1.779

37.5

18.8

undetermined

N/A

1.819

61.3

30.6

undetermined

N/A

1.811

131.3

65.6

17.14

0.89

1.750

38.8

19.4

18.80

0.08

2.434
2.000
1.500
2.750
1.734
2.042
2.665
1.500
4.500
5.000
1.500
1.625
2.355
1.500
0.625
0.834
2.095
1.200
2.200
2.084
8.188
5.000
1.684
3.179
1.000
1.800

28.8
25.0
21.3
8.8
25.0
17.5
16.3
13.8
18.8
12.5
8.8
16.3
30.0
11.3
21.3
18.8
25.0
17.5
12.5
23.8
25.0
17.5
22.5
27.5
15.0
11.3

14.4
12.5
10.6
43.8
12.5
87.5
81.3
68.8
93.8
62.5
43.8
81.3
15.0
56.5
10.7
94.0
12.5
87.5
62.5
11.9
12.5
87.5
11.3
13.8
75.0
56.5

21.19
17.52
18.41
undetermined
20.48
18.99
20.22
28.00
26.41
27.23
23.48
26.37
19.97
20.97
20.71
31.70
20.69
23.90
25.15
19.61
undetermined
25.10
20.79
20.28
24.02
23.42

0.08
0.05
0.01
N/A
0.08
0.08
0.25
2.30
2.13
0.34
0.09
1.41
0.07
0.61
0.14
0.53
0.17
1.24
1.30
0.15
N/A
0.38
0.20
0.00
0.21
0.11

PCR Results
Average
Average
DNA
260/280
DNA Conc.
Conc. per
Ratio
Mean CT
(ng/µl; n=2)
PCR rxn.
SD
(n=2)
Value (n=2)
CRE 027
1.072
17.5
87.5
19.79
0.85
CRE 028
0.417
3.8
19.0
24.91
0.08
CRE 029
0.834
15.0
75.0
undetermined
N/A
CRE 030
1.000
20.0
100.0
25.94
0.08
CRE 031
1.272
18.8
94.0
18.12
0.13
CRE 032
1.083
16.3
81.5
21.81
0.17
CRE 033
0.650
7.5
37.5
undetermined
N/A
CRE 034
1.104
21.3
10.7
19.04
0.16
CRE 035
1.134
21.3
10.7
19.72
0.03
CRE 036
1.205
21.3
10.7
undetermined
N/A
CRE 037
1.250
25.0
12.5
19.12
0.06
CRE 038
1.526
36.3
18.2
17.49
0.07
CRE 039
1.188
20.0
100.0
undetermined
N/A
CRE 040
2.028
47.5
23.8
undetermined
N/A
CRE 041
1.258
31.3
15.7
19.26
0.07
CRE 042
1.143
17.5
87.5
undetermined
N/A
CRE 043
1.320
35.0
17.5
18.35
0.05
CRE 044
1.370
32.5
16.3
21.13
0.30
CRE 045
0.033
2.5
12.5
23.91
0.37
CRE 046
1.252
37.5
18.8
18.23
0.03
CRE 047
1.438
23.8
11.9
18.80
0.04
CRE 048
1.243
37.5
18.8
18.70
0.00
CRE 050
1.091
33.8
16.9
undetermined
N/A
CRE 051
1.774
28.8
14.3
19.59
0.02
CRE 052
2.000
30.0
15.0
undetermined
N/A
CRE 053
1.835
42.5
21.3
18.18
0.03
CRE 054
1.956
36.5
18.3
17.92
0.06
CRE 055
1.772
40.0
20.0
18.81
0.01
CRE 056
1.571
27.5
13.8
18.74
0.21
Conc. = concentration; ATCC = American Type Culture Collection; rxn. = reaction; SD = standard
deviation. aCRE 017 and CRE 019 are from the same patient.
Test Organism/Sample
Identification
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